tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BriaCell Reports Increased Losses in Latest Financials

Story Highlights
  • BriaPro Therapeutics filed its financial statements for periods ending April 30, 2025.
  • Increased operating losses due to higher R&D expenses may affect financial positioning.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
BriaCell Reports Increased Losses in Latest Financials

Elevate Your Investing Strategy:

BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.

On June 16, 2025, BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., filed its unaudited condensed interim consolidated financial statements for the three and nine-month periods ending April 30, 2025, with Canadian securities commissions. The financial statements reveal an increase in operating losses compared to the previous year, reflecting higher research and development expenses, which may impact the company’s financial positioning and stakeholder interests.

The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics Corp. operates in the biotechnology industry, focusing on developing targeted immunotherapy treatments for cancer. The company is primarily engaged in advancing its proprietary immunotherapy technology to treat breast cancer, with a market focus on innovative cancer therapies.

Average Trading Volume: 16,765

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$24.58M

For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1